A randomised, double-blind, single-dose study to evaluate the pharmacokinetic, safety, tolerability, immunogenicity and pharmacodynamic profile of ISU305 compared to Soliris (Eculizumab) in Healthy Male Volunteers
Latest Information Update: 17 Dec 2020
At a glance
- Drugs Eculizumab (Primary)
- Indications Atypical Haemolytic Uraemic Syndrome; Paroxysmal nocturnal haemoglobinuria
- Focus Pharmacokinetics
- Sponsors ISU Abxis
- 27 Feb 2020 Status changed to completed.
- 04 Jul 2019 New trial record